Adaptin Bio opens enrollment in Phase 1 trial of APTN-101 for glioblastoma

ADAPTIN BIO, INC.

Enrollment opened in Phase 1 open-label dose-escalation trial of APTN-101 (BRiTE T-cell engager) for EGFRvIII-positive GBM, at Duke University, up to 15 adult patients.
Primary endpoint is proportion of patients with dose-limiting toxicity per dose level; secondary endpoints include pharmacokinetics and objective response rate (modified RANO).
Preclinical data: APTN-101 showed >7-fold increase in brain distribution vs EGFRvIII engager alone and complete tumor eradication in 70-80% of mice models.
GBM is ~15,000 new U.S. cases/year; market valued at $3.02B (2025), projected $4.44B by 2030 (8% CAGR).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.